ERR2278881
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.480
- ALLOGRAFT_REJECTION+0.470
- IL6_JAK_STAT3_SIGNALING+0.440
- TNFA_SIGNALING_VIA_NFKB+0.390
- UV_RESPONSE_DN+0.380
- INFLAMMATORY_RESPONSE+0.370
- WNT_BETA_CATENIN_SIGNALING+0.350
- HEDGEHOG_SIGNALING+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.570
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.510
- MTORC1_SIGNALING-0.480
- CHOLESTEROL_HOMEOSTASIS-0.400
- FATTY_ACID_METABOLISM-0.390
- DNA_REPAIR-0.330
- PEROXISOME-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.934 |
| 2 | SRR1516085 | — | — | 0.930 |
| 3 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.929 |
| 4 | C3N-03233 | — | cohortA1 | 0.927 |
| 5 | R163 | — | — | 0.925 |
| 6 | TCGA-A2-A25A-01A-12R-A16F-07 | — | A | 0.924 |
| 7 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.922 |
| 8 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.919 |
| 9 | SRR8518138 | — | D | 0.918 |
| 10 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |